NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Forecast, Price & News $2.87 -0.05 (-1.71%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$2.83▼$2.9350-Day Range$1.64▼$3.2152-Week Range$1.60▼$3.79Volume242,607 shsAverage Volume643,376 shsMarket Capitalization$496.73 millionP/E RatioN/ADividend YieldN/APrice Target$8.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Autolus Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside182.8% Upside$8.20 Price TargetShort InterestHealthy0.43% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.88) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.49 out of 5 starsMedical Sector103rd out of 986 stocksBiological Products, Except Diagnostic Industry12th out of 163 stocks 3.5 Analyst's Opinion Consensus RatingAutolus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.20, Autolus Therapeutics has a forecasted upside of 182.8% from its current price of $2.90.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.43% of the outstanding shares of Autolus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Autolus Therapeutics has recently decreased by 14.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUTL. Previous Next 2.3 News and Social Media Coverage News SentimentAutolus Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Autolus Therapeutics this week, compared to 2 articles on an average week.Search Interest8 people have searched for AUTL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.06% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.88) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Autolus Therapeutics (NASDAQ:AUTL) StockAutolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.Read More Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AUTL Stock News HeadlinesJune 7, 2023 | americanbankingnews.comAutolus Therapeutics (NASDAQ:AUTL) Shares Up 9%June 6, 2023 | finance.yahoo.comAutolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023June 9, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.June 2, 2023 | markets.businessinsider.comNeedham Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)June 2, 2023 | markets.businessinsider.comWhere Autolus Therapeutics Stands With AnalystsJune 2, 2023 | americanbankingnews.comAutolus Therapeutics (NASDAQ:AUTL) Stock Price Down 7.5%May 23, 2023 | americanbankingnews.comSeagen (NASDAQ:SGEN) and Autolus Therapeutics (NASDAQ:AUTL) Critical ReviewMay 12, 2023 | finance.yahoo.comAutolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHAJune 9, 2023 | Vantage Point (Ad)Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. May 12, 2023 | americanbankingnews.comAutolus Therapeutics plc (NASDAQ:AUTL) Short Interest UpdateMay 7, 2023 | seekingalpha.comAutolus Therapeutics plc 2023 Q1 - Results - Earnings Call PresentationMay 6, 2023 | americanbankingnews.comAutolus Therapeutics (NASDAQ:AUTL) Price Target Cut to $6.00 by Analysts at Wells Fargo & CompanyMay 6, 2023 | msn.comWells Fargo Maintains Autolus Therapeutics plc - ADR (AUTL) Overweight RecommendationMay 4, 2023 | finanznachrichten.deAutolus Therapeutics plc: Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational ProgressMay 4, 2023 | finance.yahoo.comAutolus Therapeutics Reports First Quarter 2023 Financial Results and Operational ProgressMay 3, 2023 | msn.comPreview: Autolus Therapeutics's EarningsApril 28, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Autolus TherapeuticsApril 27, 2023 | finance.yahoo.comAutolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCOApril 26, 2023 | finance.yahoo.comAutolus Therapeutics Announces Publication in Molecular Therapy Nucleic AcidsApril 26, 2023 | finance.yahoo.comAutolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual MeetingApril 25, 2023 | finance.yahoo.comAutolus Therapeutics to Host Virtual Capital Markets DayApril 24, 2023 | americanbankingnews.comAutolus Therapeutics' (AUTL) Buy Rating Reiterated at Needham & Company LLCApril 21, 2023 | msn.comNeedham Reiterates Autolus Therapeutics plc - ADR (AUTL) Buy RecommendationApril 21, 2023 | markets.businessinsider.comAutolus Therapeutics (AUTL) Receives a Buy from NeedhamApril 20, 2023 | finance.yahoo.comAutolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023April 17, 2023 | americanbankingnews.comShort Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Increases By 40.5%April 14, 2023 | finance.yahoo.comAutolus Therapeutics (NASDAQ:AUTL) shareholders have endured a 79% loss from investing in the stock three years agoSee More Headlines AUTL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUTL Company Calendar Last Earnings5/04/2023Today6/09/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUTL CUSIPN/A CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees324Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.20 High Stock Price Forecast$12.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+180.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-148,840,000.00 Net MarginsN/A Pretax Margin-2,328.35% Return on Equity-64.42% Return on Assets-39.68% Debt Debt-to-Equity RatioN/A Current Ratio9.94 Quick Ratio9.94 Sales & Book Value Annual Sales$6.36 million Price / Sales79.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book1.69Miscellaneous Outstanding Shares173,070,000Free Float128,595,000Market Cap$505.36 million OptionableNot Optionable Beta1.56 Key ExecutivesChristian Martin ItinChief Executive Officer & DirectorChristopher VannChief Operating Officer & Senior Vice PresidentLucinda CrabtreeChief Financial OfficerMartin PuléChief Scientific Officer & Senior Vice PresidentDavid BrochuChief Technical Officer & Senior Vice PresidentKey CompetitorsAura BiosciencesNASDAQ:AURATarsus PharmaceuticalsNASDAQ:TARSAlloVirNASDAQ:ALVRCullinan OncologyNASDAQ:CGEMKodiak SciencesNASDAQ:KODView All CompetitorsInstitutional OwnershipJPMorgan Chase & Co.Sold 52,484 shares on 5/18/2023Ownership: 0.255%Armistice Capital LLCSold 552,000 shares on 5/16/2023Ownership: 5.588%Alyeska Investment Group L.P.Sold 1,250,000 shares on 5/16/2023Ownership: 0.124%State Street CorpBought 47,690 shares on 5/16/2023Ownership: 0.058%Jane Street Group LLCBought 95,876 shares on 5/16/2023Ownership: 0.055%View All Institutional Transactions AUTL Stock - Frequently Asked Questions Should I buy or sell Autolus Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUTL shares. View AUTL analyst ratings or view top-rated stocks. What is Autolus Therapeutics' stock price forecast for 2023? 5 brokerages have issued twelve-month target prices for Autolus Therapeutics' shares. Their AUTL share price forecasts range from $5.00 to $12.00. On average, they predict the company's stock price to reach $8.20 in the next year. This suggests a possible upside of 180.8% from the stock's current price. View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts. How have AUTL shares performed in 2023? Autolus Therapeutics' stock was trading at $1.90 at the start of the year. Since then, AUTL shares have increased by 53.7% and is now trading at $2.92. View the best growth stocks for 2023 here. Are investors shorting Autolus Therapeutics? Autolus Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 739,700 shares, a decline of 14.1% from the April 30th total of 861,000 shares. Based on an average trading volume of 573,600 shares, the short-interest ratio is presently 1.3 days. View Autolus Therapeutics' Short Interest. When is Autolus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our AUTL earnings forecast. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics plc (NASDAQ:AUTL) announced its earnings results on Thursday, May, 4th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05. The firm had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.09 million. What ETFs hold Autolus Therapeutics' stock? ETFs with the largest weight of Autolus Therapeutics (NASDAQ:AUTL) stock in their portfolio include Harbor Disruptive Innovation ETF (INNO).iShares Biotechnology ETF (IBB). What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD). When did Autolus Therapeutics IPO? (AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. What is Autolus Therapeutics' stock symbol? Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL." Who are Autolus Therapeutics' major shareholders? Autolus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (5.59%), Perpetual Ltd (1.07%), BlackRock Inc. (0.51%), JPMorgan Chase & Co. (0.25%), MAI Capital Management (0.25%) and ExodusPoint Capital Management LP (0.24%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Autolus Therapeutics' stock price today? One share of AUTL stock can currently be purchased for approximately $2.92. How much money does Autolus Therapeutics make? Autolus Therapeutics (NASDAQ:AUTL) has a market capitalization of $505.36 million and generates $6.36 million in revenue each year. The company earns $-148,840,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. How many employees does Autolus Therapeutics have? The company employs 324 workers across the globe. How can I contact Autolus Therapeutics? Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The official website for the company is www.autolus.com. The company can be reached via phone at 442038296230 or via email at ir@autolus.com. This page (NASDAQ:AUTL) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.